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Objectives: Neuromodulation of the immune system has been proposed to be 
influenced by hemispheric lateralisation (HL). The present study tested whether HL 
predicted CD4+ levels, statistically controlling for confounders.  
Methods: Employing two assessments of HL, 68 HIV-1+ patients were followed 
prospectively. Numerous exclusion criteria and confounder assessments were 
employed (e.g., age, medication).  
Results: Left-HL significantly positively predicted CD4+ levels at follow-up, and this 
was moderated by medication (HAART) status: Only in HAART-naïve patients, did 
HL predict CD4 levels Furthermore, HL significantly predicted whether patients were 
in a clinically significant high/low CD4+ count level. 
Conclusions: The present work partly corroborated the theory of HL influences on 
immunity, extended it to HIV immunity and identified a moderator: HAART 
medication, using a more rigorous methodology. Implications for future research and 
treatments are provided. 
 
 
 
 
 
 
Introduction 
Since its discovery over 30 years ago, human immunodeficiency virus (HIV) has been 
one of the most widely studied viruses in medical history. Whilst much is known 
about how prognosis varies between patients, there is still a large proportion of this 
variance thus far unexplained [1, 2]. One potential means of explaining some of this 
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variance comes from neuroimmune influences, and more specifically from 
Hemispheric Lateralisation (HL) and its effects on the immune system. HL refers to 
the stable tendency to activate or relay functions of one hemisphere more than the 
other (e.g. [3, 4]). A recent review has suggested an immunopotentiating role for the 
left hemisphere, and an immunosuppressant role for the right hemisphere [5]. 
However very little confounder control has been exerted in studies so far and 
therefore the HL-immune relationship requires substantiation with stricter 
methodological control, and exploration of mediating and moderating variables.  
One study has examined the implications of HL on HIV prognosis by examining the 
longitudinal immune correlates of HL in HIV [6]. Gruzelier et al. found that left HL 
was associated with better immune outcomes (CD4+, CD8+ T-cells) at a 30 month 
follow up. Furthermore, their study also described a relatively poorer prognosis in 
those patients with right HL. However, their sample was small (N=26) and relatively 
uniform. Most importantly, Gruzelier et al. did not control for effects of baseline 
immune parameters and other confounders (e.g., mood, mode of infection, other 
illnesses) that may affect the central and autonomic nervous system (ANS) or the 
course of HIV [7]. Additionally, the study did not selectively recruit right-handed 
participants, a measure which is central in HL research. Left handed individuals 
characterise atypical interhemispheric communication and hemispheric specialisation 
[8, 9]. Finally, the research was conducted before the advent of highly-active 
antiretroviral therapy (HAART), one of the most significant developments in HIV 
medicine [10]. These limitations question the validity of their inferences, and the 
application of the findings to modern HIV patients and treatment.  
The present study aimed to extend the findings of the Gruzelier group and examine 
the prospective relationship between HL and CD4+ T-cell counts in HIV-1+ patients, 
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with better methodological and statistical control. Methodologically, a larger sample 
of participants was sought from broader demographic profiles. Only right-handed 
participants were recruited to eliminate the heterogeneity observed in HL amongst left 
handed and ambidextrous people. Additionally, strict exclusion factors were 
implemented to reduce confounds. Statistically, the influence of relevant confounders 
was tested as well. The present study also aimed to identify and evaluate potential 
variables that may moderate or mediate the relationship between HL and HIV 
prognosis. Identified a priori, mood, HAART medication status and adherence and 
duration of HIV infection were selected as potential moderating or mediating 
variables due to their influence on immune status and trajectory in HIV disease (e.g. 
[11, 12]). It was hypothesised that left-HL would predict a better immune outcome in 
asymptomatic HIV patients.  
 
Methods 
Participants & Recruitment Criteria 
The participant sample (N=68) was drawn from a clinical population of HIV+ 
outpatients of a hospital located in Brussels, Belgium. Inclusion criteria for the study 
were: right-handedness; asymptomatic HIV-1 disease (CD4+ T-cell count> 200/mm3); 
good literacy and verbal fluency in Flemish, French or English; patients aged between 
18 and 80 years of age; and no presence of cognitive deficits. The exclusion criteria 
were based on three research requirements; cognitive capability, extraneous 
modulation of HIV disease course and extraneous modulation of the communication 
between the brain and the immune system. Cognitive capability was ascertained by 
including patients scoring >25 on the Mini Mental State Examination (MMSE: [13]) 
with candidates scoring lower than 25 being excluded from further participation. 
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Patients who had a diagnosis of any psychiatric illness were excluded. Additionally 
patients who were pregnant, or had been diagnosed with a neurological disorder, an 
autoimmune disease, or were receiving either immune-modulating (outside of 
HAART regimens) or autonomic nervous system modulating drugs were excluded. 
Any patients that had a medical history of dependence to or abuse of alcohol, 
methamphetamine or cocaine were excluded. Further, any medical history of 
clinically meaningful brain damage was an indicator for study exclusion.  
 
Measures & Materials 
HL was assessed using two measures; the Hemispheric Preference Test (HPT: [14]) 
and a computerised variant of the Line Bisection Test (LBT: [15]) using prebisected 
lines. The HPT includes 20 items, with 10 items reflecting either right or left 
characteristics (e.g., visualisation, strategic thinking, respectively). A “left” index of 
the HPT was calculated using the formula left-HL=100x(Left-Right)/(Left+Right). In 
the LBT, participants estimated which side of a prebisected line was larger, when both 
in fact were equal. Both tests have been validated against EEG measures of HL [16, 
17]. CD4+ T cell count was obtained from the participants’ medical files three months 
before study entry (T1), at study entry (T2) and three months later (T3). Mood was 
assessed using the Hospital Anxiety and Depression Scale (HADS: [18]) and 
adherence to HAART was measured using the Morisky Medication Adherence Scale 
[19]. Participants were surveyed for their socio-demographic background, HIV-
relevant history (mode of infection, time since diagnosis etc.) and health behaviour 
(e.g. addictive substance use, condom use, number of sexual partners in the previous 
year).  
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Procedure 
Data was collected over three time points (T1, T2, T3). A retrospective medical 
baseline (T1) for T-cell data was adopted, to have a longer follow-up between 
immune outcomes. At study entry (T2), participants were screened with the MMSE, 
and were given a semi-structured interview for demographic information and 
adherence. Participants’ HL was measured by the HPT and the LBT at T2.  
Follow-up data collection was conducted at approximately three months post study 
entry (T3).  
 
Statistical Analysis 
All data analyses were run using the calculated left HL index with a square-root 
transformation of the scores, and a corresponding LHL index of the LBT. 
Confounders in relation to CD4+ at T3 were assessed statistically from the available 
data using bivariate Pearson’s correlations for continuous data (e.g., age, time since 
diagnosis) and t test or ANOVA for categorical data (e.g. ethnicity, mode of 
contraction). Those variables that presented significant (p<.05) associations with 
CD4+ at T3 were used as covariates in each correlation. Analyses were conducted 
using Spearman’s rho correlation in order to counteract bias due to outliers within the 
dataset. To ensure that confounding variables were still controlled for in these tests 
using the Spearman’s rho, the T3 CD4+ scores (dependent variable) were residualised 
on medication variables and/or T1 CD4+ data, which emerged as the significant 
confounders. The relationship between left-HL and these residualised scores were 
then examined by Spearman’s rho correlations.  Moderator analyses were repeated 
using Spearman’s rho correlation, split by moderator subgroup (e.g. HAART/non-
HAART).  The statistical and clinical significance of these results was then tested 
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using logistic regression where the dependent variable was a clinically significant cut-
off of CD4+ outcome data. Participants’ outcome (T3) CD4+ T-cell levels were 
categorised into high (CD4+ T-cell count> 500/mm3) or low (CD4+ T-cell count< 
350/mm3) and analysed against the T1 CD4+ scores, use of HAART and left-HL 
scores. 
 
Results 
Sample Characteristics 
The original sample size was 72, and four participants had to be excluded from final 
analyses. These were due to comprehension problems (N=3) and outlying HPT data 
(N=1). Table 1 shows the summary composition of the sample. 
 
Hemispheric Lateralisation and Immunity in HIV 
Among all confounders, only baseline (T1) CD4+ T-cell count and HAART were 
significantly associated with T3 CD4+, hence we controlled for their effects. A 
Spearman’s rho correlation was conducted between the standardised prospective 
CD4+ T-cell measurement (CD4+ T3, residualised on CD4+ T1 and HAART 
medication as covariates) and the square-root transformation of the Hemispheric 
Preference Test (SQRT HPT). There was a statistically significant correlation 
between left-HL and standardised outcome CD4+ T-cell count (rho=.234, p= .047, one 
tailed test, N=61). 
 
Moderator Analyses 
Ethnicity 
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A potential moderating factor was identified in ethnicity (African or European 
origination), by the observation of potential relationships between this variable and 
several other variables (e.g. gender, mode of HIV contraction, sexual orientation). No 
significant difference was observed between outcome (T3) CD4+ counts for these two 
groups (t(58)= 1.75, p=.086). Spearman’s rho correlations were conducted between the 
standardised prospective CD4+ T-cell measurement (CD4+ T3, residualised on CD4+ 
T1 and HAART medication) and the square-root transformation of the Hemispheric 
Preference Test (SQRT HPT) as predictor, split by ethnicity group. There were no 
statistically significant correlations between left HPT and standardised outcome CD4+ 
T-cell count for the European sub-sample (rho=.241, p= .081, one tailed test, N=35), 
though a trend was observed for the African sub-sample (rho=.402, p= .055, one tailed 
test, N=17). 
 
HAART Medication 
A significant difference was observed between patients with and without HAART 
treatment in T3 CD4+ counts (t(50.80)= 2.06, p=.045), with those taking HAART having 
the higher levels of outcome T-cell count. HAART was presented as a potential 
moderator due to its immunomodulating effects within HIV disease, and the large 
proportion of participants (N= 48, 70.6%) reporting to be undergoing HAART 
treatment. Spearman’s rho correlations were conducted between the standardised 
prospective CD4+ T-cell measurement (CD4+ T3 residualised on CD4+ T1) and SQRT 
HPT as predictor, split by treatment group. There was no statistically significant 
correlation between left HPT scores and standardised outcome CD4+ T-cell count for 
the HAART treated sub-sample (rho=.153, p= .170, one tailed test, N=41). In contrast, 
there was a statistically significant correlation between left HPT scores and 
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standardised outcome CD4+ in the non-HAART group (rho=.627, p= .019, one tailed 
test, N=11; see figure 1).  
 
Assessment of HL to predict clinically significant outcome CD4+  T-cell count 
In order to explore whether the clinical categorisation of T3 (outcome) CD4+ T-cell 
count (high= CD4+>500/mm3; low= CD4+<350/mm3) is influenced by left HL, 
controlling for baseline (T1) CD4+ T-cell count and HAART medication status, a 
binary logistic regression model was performed. The results from the logistic 
regression are presented in table 2 and show that both T1 CD4+ T-cell count and left-
HL (SQRT HPT) scores significantly predicted the clinically-significant 
categorisation of CD4+ T-cell levels at T3. Additionally we tested for an interaction 
between HAART and left HL with either a linear regression for the continuous 
outcome CD4+ (T3), or a logistic regression for the categorical outcome of high 
versus low CD4+. Both regressions testing this interaction were non-significant 
(p>.05). Analysis of the cells of the interaction provided very small sample sizes for 
the non-HAART treated sub-group (low CD4+ N=5; high CD4+ N=4) against the 
HAART-treated sub-group (low CD4+ N=11; high CD4+ N=28). 
 
Discussion 
Hemispheric Lateralisation & Prospective CD4+  T-cell Count 
The present study sought to examine the predictive ability of HL in relation to 
prognosis in HIV-1+ patients. The main finding showed a significant, positive 
relationship between left HL and prospective CD4+ T-cell count. This finding, albeit 
relatively modest, is in line with those found in a previous HIV+ patient sample [6] 
and amongst the wider literature describing a relationship between left HL and better 
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immunity [5]. Further, the logistic regression uncovers a clinically significant 
relationship between outcome CD4+ T-cell count category (high versus low) and left 
HL, controlling for confounders. This finding suggests that HL could serve as a 
clinical predictor of CD4+ T-cell loss trajectory, and therefore an indicator of potential 
intervention both determined by HL and targeting HL.  
 
Moderation 
The analysis for moderation by ethnicity did not attain statistical significance, 
however a trend was indicated. The analysis for moderation by medication group 
provided a significant, positive relationship between left HL and prospective 
immunity only in those patients who were not receiving antiretroviral treatment. This 
analysis indicated that approximately 39.3% of the variance observed in outcome 
CD4+ levels could be attributed to LHL, controlling for baseline CD4+ counts. These 
new findings present a new dimension to, and the effect size is clinically significant 
for, the current knowledge on HL in HIV disease. However, when this moderator was 
tested by examining interactions for both continuous and categorical CD4+ outcomes 
the findings were not significant. It is possible that this lack of support from these 
tests may be attributable to insufficient data in one or more of the cells of the 
interaction, but it does mean that viewing HAART as a moderator in this relationship 
should be viewed with caution until the findings can be replicated in a larger sample.  
Why left HL may be predictive of CD4+ outcome in treatment-naïve patients, but not 
HAART-treated patients, is not clear. It is possible that if both left HL and HAART 
are working in unison toward immunopotentiation, that the effects of HL in the 
presence of HAART may be masked. This explanation is partially substantiated when 
examining other immune cells affected in the same way by HL and HIV. For 
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example, induction of HAART treatment has been shown to affect (amongst others) 
lymphocyte proliferation and neutrophil function [20, 21]. These immune measures 
have also been demonstrated to be asymmetrically influenced by HL [22, 23]. It is 
possible that lacking HAART enables HL to manifest its immunomodulatory effects. 
Should this finding be replicated, it has vast implications for countries where access to 
HAART is limited, as activating the left hemisphere can enhance immunity [24]. 
 
 
Limitations 
The present study’s sample size was restricted due to missing data, and the dataset 
held prevailing skewness even after data transformation. Further, the sub-sample 
analyses groups were not equal in type or composition. As HAART was used as a 
moderating variable, control based on line and type of HAART treatment may further 
elucidate these findings. The period of follow-up was significantly shorter (≈ 6 
months) than the 30 month follow-up employed by the Gruzelier group [6]. Finally, 
the HL assessments themselves were a deviation from the precedent of EEG 
employed by Gruzelier et al. [6], although the measures were validated by EEG.  
Nevertheless, our results support the HL-immune relations reviewed recently [5] and 
extend them to HIV with more rigourous methodology.  
 
Future Directions 
Further assessment of this relationship within the HIV context is required, most 
specifically the potential moderating implication of ethnicity and of HAART. 
Analysis of the quality of moderation by HAART may also provide useful 
information (i.e. first or second line treatments, types of medication etc.). Should 
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more empirical evidence support the role of HL in HIV prognosis, targeted 
interventions can be devised at relatively low cost, with high mobility to reach those 
areas still under a heavy HIV burden. These include testing whether activating the left 
hemisphere, by focused cognitive exercises that activate that hemisphere, could 
possibly affect CD4+ levels in patients not receiving HAART. 
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Table 1. Descriptive statistics of continuous data with mean, standard deviation and number of 
respondents. 
 
Characteristic Mean  SD N 
Age (years)  Whole sample 43.30 8.95 68 
Gender Male   51 
Female   18 
Ethnicity African   23 
European   46 
Medication HAART-treated   48 
HAART-naive   20 
Duration of HIV (years) [64.2% sexually contracted] 6.32 6.36 64 
MMSE (maximum range 25-30) 29.03 1.25 68 
Mean period between clinic visits (days) 109.97 33.98 65 
Non-Adherence (maximum range 0-4, 4 indicating maximum non-
adherence) 
.55 .77 47 
HADS Anxiety (maximum range 0-21) 7.22 4.37 68 
HADS Depression (maximum range 0-21) 4.13 3.54 68 
Line Bisection Index of Left Lateralisation (maximum range 0-10) 5.46 2.64 68 
HPT Left Lateralisation Index Z Score  
(based on square-root transformation) 
3.05 .073 61 
CD4+ 
(cells/mm3) 
T1: Retrospective data point (3 months) 571.31 251.92 61 
T2: Study entry  567.64 263.29 66 
T3: Prospective data point (3 months) 545.90 242.28 60 
 
 
 
 
 
 
Table 2. Logistic regression analysis of outcome CD4+ T-cell levels, left HL (SQRT HPT), baseline 
CD4+ T-cell levels and HAART medication status. 
 
 B S.E. Wald df Sig. Exp (B) 95% C.I. for EXP 
(B) 
Lower Upper 
Step CD4 (T3) .022 .008 7.696 1 .006 1.022 1.006 1.038 
HAART -.715 1.464 .238 1 .625 .489 .028 8.626 
LHPT (SQRT) .971 .428 5.139 1 .023 2.641 1.141 6.114 
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Figure 1. A scatterplot showing the correlation between left hemispheric lateralisation and standardised 
CD4+ T-cell count at follow-up (T3) for the non-HAART sub-sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
